February 24, 2026
San Jose, California, February 21, 2026 — Rapalogix Health, a biotechnology company advancing a science-first approach to cellular longevity and skin health, announced today that it has received 2026 Beauty & Longevity CHOICE Awards for “Start-Up Of The Year” and “Cellular Signaling & Advanced Longevity Mechanisms” at the 2026 INNOCOS Beauty, Tech & Longevity Summit: The Future of Intelligent Beauty, Silicon Valley.
The INNOCOS Beauty & Longevity CHOICE Awards is an annual program celebrating innovation at the intersection of beauty, wellness, and technology, judged by a distinguished panel of scientists, longevity experts, and industry thought leaders. The Cellular Signaling & Advanced Longevity Mechanisms category specifically honors innovations where biotech engineering, not surface treatment alone, drives transformation, enabling skin cells to repair, renew, and reorganize with greater precision. The award recognizes breakthrough topical innovations informed by advanced cell-signaling approaches, including modalities such as exosomes, secretomes, ECM-derived peptides, autophagy activators, and telomere-supporting actives that reflect communication pathways studied in regenerative medicine.
Rapalogix Health was recognized for RLX-201, its proprietary pro-longevity molecule, and Re-Q Pro-Longevity Face Serum, the first product from its professional skincare brand, Re-Q Health. RLX-201 is a patented pro-longevity molecule designed to restore youthful cellular function through modulation of mTORC1 activity in the skin. Judges evaluated entries across five core pillars: Scientific Evidence & Innovation, Mechanism of Action Related to Longevity, Efficacy & Measurable Outcomes, Formulation Integrity & Bioavailability, and User Experience & Market Impact. Rapalogix Health distinguished itself through its durable biological rationale, well-defined mechanism of action, and strong translational potential.
“We are proud to stand alongside leaders in longevity science and beauty biotech, and to see our platform recognized for its potential to meaningfully influence how we approach skin aging,” said Rahul Mehta, PhD, CEO and Co-Founder of Rapalogix Health. “Our goal is to move the category toward mechanism-driven skin health, grounded in cellular biology, and recognition from INNOCOS reinforces that direction for the field.”
About Rapalogix Health
Rapalogix Health is a New York-based biotechnology company pioneering the next evolution in skin health. We translate foundational insights in longevity science into transformative dermatological solutions. Grounded in a science-first approach, the company is developing an innovative pipeline of prescription therapeutics and professional skincare products. Re-Q Pro-Longevity Face Serum, the first product from Rapalogix’s professional skincare brand, Re-Q Health, is now available at select dermatology practices in the United States. Re-Q Pro-Longevity Face Serum is powered by RLX-201, Rapalogix’s proprietary pro-longevity molecule designed to reset and restore exhausted skin cells, extend their longevity, and deliver healthy and youthful skin over a lifetime.
For more information on Rapalogix Health, visit www.rapalogix.com or follow Rapalogix on LinkedIn and Instagram.
For more information on Re-Q Health, visit www.reqhealth.com or follow Re-Q Health on Instagram.
About INNOCOS
INNOCOS is a platform convening innovators, scientists, investors, and brands at the frontier of beauty, wellness, and longevity science. Through its longevity summits, awards programs, and community initiatives, INNOCOS spotlights science-backed products and technologies shaping the future of healthspan and beauty. The Beauty & Longevity CHOICE Awards honor the most innovative, science-backed products and technologies recognized by a panel of leading longevity researchers, physicians, and industry thought leaders. Learn more at innocosevents.com.
